Figure 13. H3.3-G34R pHGG shows an improved therapeutic response to a STING agonist, and a STING inhibitor diminishes RT and DDRi efficacy.

(A) Illustration depicting the time frame of the combined treatment with DDRi, RT, and the STING agonist diABZI. (B) Survival of H3.3-G34R–bearing mice treated with RT alone or with RT in combination the STING agonist diABZI. (C) Illustration depicting the time frame of the combined treatment with DDRi, RT, and the STING inhibitor H151. (D) Survival of H3.3-G34R–bearing mice that received no treatment or that were treated with RT alone; the STING inhibitor H151 alone; or with RT in combination with H151, H151 plus CHK1/2i, or H151 plus the PARPi pamiparib. n = 5 mice/group. **P < 0.01; log-rank (Mantel-Cox) test.